Florida’s Democratization of mAb Access for COVID-19 Working—So Biden Cuts Supply by Over 50%
https://trialsitenews.com/flor…n-cuts-supply-by-over-50/
Although Florida represents among the worst, if not the most severely hit of states in this most recent Delta variant-driven surge, the Biden administration recently cut back the state’s supply of monoclonal antibodies (mAbs) as part of a rationing program. Florida’s Governor Rick DeSantis and POTUS have been at odds over approach to the pandemic, perhaps driven by deeper underlying life philosophies and associated convictions. With a less vaccinated population, DeSantis aggressively rolled out monoclonal antibody infusion centers to care for people around the state. This approach appears to be working with a marked reduction in new COVID-19 infections recorded. However, deaths are still high, indicating the importance of monoclonal antibody access. But what a difference a few weeks make. Just a few weeks ago, Florida was receiving 40,000 treatments per week, but that supply was cut to under 18,000 doses of the Regeneron monoclonal antibody. DeSantis, in an urgent move to help the people of the state, ordered 3,000 doses of the new monoclonal antibody treatment from GlaxoSmithKline. This by no means makes up for the over 55% cut in doses. Why would POTUS cut the supply of life-saving therapies under emergency use authorization (EUA) to arguably the present-day worst-hit state during this stage of the COVID-19 pandemic?
DeSantis Democratization of mAbs Working
With more than 25 monoclonal antibody infusion sites around the state, the work by DeSantis appears to be paying off big time. For example, on August 16—the apex of the Delta surge in Florida—the state reported 56,036 cases in one day, shattering old records there. Just a month-and-a-half later and the daily case count stands at 8,804 and a 7-day average totaling 7,303.
According to local news NBC Miami, the democratization of the mAbs is, in fact, working, but now Governor DeSantis warns the drastic cut may force closures. Meaning the entire premise for the DeSantis democratization of COVID-19 is at stake. Did these cuts have any political underpinnings? TrialSite’s “Drugs, Power & Politics” point of view suggests that politics, unfortunately, could be a distinct possibility.
Horrible Consequences
In badly hit parts of the state, such as Tampa Bay, local hospitals are hurting from the loss of mAb supply. John Couris, CEO of Tampa General Hospital, reports the Biden decision to cut the state’s supply of mAbs, calling it in a recent meeting “plain wrong.”
As reported in NBC, Miami Couris declared, “I don’t know why they did it, because the supply chain was working perfectly the way it was,” Couris said before the Florida House Pandemics and Public Emergencies Committee. “This change is going to hurt people in Florida. It’s already starting to make us, for example, think about how we are going to have to limit the hours of operations associated with our ability to provide this life-saving therapy.”
Part of A Bigger Agenda?
POTUS issued an unprecedented federal mandate to use executive branch power to compel nearly 100 million people to receive a COVID-19 vaccine. While making that announcement, Biden expressed his frustration with those unvaccinated people, indicating the wrath now felt in Florida—that Biden moved to punish the residents of Florida. Perhaps not intended in this way, health authorities are essentially corralling the population to get vaccinated or pay the consequences.
The off-label use of ivermectin, for example, was targeted starting about six months ago in what appears to be a highly orchestrated campaign, involving the fabrication of misinformation and, in some cases, outright lies in what appears to be an attempt to identify all ivermectin (even the drug meant for humans, as merely a horse deworm pill) while attempt to secure care now are disrupted by POTUS.
https://www.miamiherald.com/ne…rus/article254397879.html
For those of you unfamiliar; Steve Colbert is a very influential talk show host here in the US:
